 |
|
Risk of Leukemia After Treatment With Pituitary Growth Hormone
Judith E. Fradkin, MD;
James L. Mills, MD, MS;
Lawrence B. Schonberger, MD, MPH;
Diane K. Wysowski, PhD;
Ruth Thomson, MPH;
Stephen J. Durako;
Leslie L. Robison, PhD
JAMA. 1993;270(23):2829-2832.
Abstract
| |
Objective.
—To determine whether pituitary-derived human growth hormone treatment increases the subsequent risk of developing leukemia and lymphoma.
Design.
—Cohort study.
Setting.
—United States.
Participants.
—A total of 6284 recipients of pituitary-derived human growth hormone distributed by the National Hormone and Pituitary Program between 1963 and 1985.
Main Outcome Measures.
—Leukemia and lymphoma.
Results.
—Three cases of leukemia occurred in 59736 patient-years of follow-up from the start of growth hormone therapy to case ascertainment at interview; this number was not significantly higher (P=.23) than the 1.66 cases expected in the US age-, race-, and gender-matched general population. Three additional cases, found in an extended follow-up that provided 83917 person-years of risk, yielded a minimum rate of leukemia that was significantly increased (six cases found, 2.26 expected; P=.028). The relative risk of leukemia in pituitary growth hormone recipients compared with the general population was 1.8 (90% confidence interval [CI], 0.82 to 7.5) for the defined follow-up and 2.6 (90% CI, 1.2 to 5.2) for the extended follow-up. Five of the six subjects who developed leukemia had antecedent cranial tumors (four craniopharyngioma, one astrocytoma) as the cause of growth hormone deficiency, and four had received radiotherapy. There was no increase in leukemia in patients with idiopathic growth hormone deficiency. The association of leukemia and craniopharyngioma was significant (P<.001). There was no excess of lymphoma in the cohort.
Conclusions.
—This cohort of growth hormone recipients had a significantly increased rate of leukemia compared with the age-, race-, and gender-matched general population. However, the upper bound CI of the relative risk in our population (5.2) is well below the other estimates (7.6). Compared with the general population, our study population had more possible risk factors for leukemia (radiation, tumor) that may have contributed to the excess observed. The clustering of cases of leukemia in craniopharyngioma patients should be further evaluated.
(JAMA. 1993;270:2829-2832)
Author Affiliations
From the Division of Diabetes, Endocrinology, and Metabolic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases (Dr Fradkin), and the National Institute of Child Health and Human Development (Dr Mills), National Institutes of Health, Bethesda, Md; the Centers for Disease Control and Prevention, Atlanta, Ga (Dr Schonberger); the Food and Drug Administration, Rockville, Md (Dr Wysowski); Westat Incorporated, Rockville, Md (Ms Thomson and Mr Durako); and the University of Minnesota, Minneapolis (Dr Robison).
Footnotes
Reprint requests to the Division of Diabetes, Endocrinology, and Metabolic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Westwood Bldg, Room 621, Bethesda, MD 20892 (Dr Fradkin).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline
Molitch et al.
J. Clin. Endocrinol. Metab. 2006;91:1621-1634.
ABSTRACT
| FULL TEXT
Safety of Growth Hormone Treatment in Pediatric Patients with Idiopathic Short Stature
Quigley et al.
J. Clin. Endocrinol. Metab. 2005;90:5188-5196.
ABSTRACT
| FULL TEXT
Effect of recombinant human GH on circulating granulocyte colony-stimulating factor and neutrophils in patients with adult GH deficiency
Sohmiya et al.
Eur J Endocrinol 2005;152:211-215.
ABSTRACT
| FULL TEXT
Risk of Disease Recurrence and Second Neoplasms in Survivors of Childhood Cancer Treated with Growth Hormone: A Report from the Childhood Cancer Survivor Study
Sklar et al.
J. Clin. Endocrinol. Metab. 2002;87:3136-3141.
ABSTRACT
| FULL TEXT
Outcomes of Growth Hormone Replacement Therapy in Survivors of Childhood Acute Lymphoblastic Leukemia
Leung et al.
JCO 2002;20:2959-2964.
ABSTRACT
| FULL TEXT
Growth Hormone Replacement Therapy in Children With Medulloblastoma: Use and Effect on Tumor Control
Packer et al.
JCO 2001;19:480-487.
ABSTRACT
| FULL TEXT
Growth Hormone Treatment of Children with Brain Tumors and Risk of Tumor Recurrence
Swerdlow et al.
J. Clin. Endocrinol. Metab. 2000;85:4444-4449.
ABSTRACT
| FULL TEXT
Growth Hormone Therapy in Adults and Children
Vance and Mauras
NEJM 1999;341:1206-1216.
FULL TEXT
Recent Status in the Occurrence of Leukemia in Growth Hormone-Treated Patients in Japan
Nishi et al.
J. Clin. Endocrinol. Metab. 1999;84:1961-1965.
ABSTRACT
| FULL TEXT
|
